A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
Phase 3
2,600
about 3.7 years
18+
4 sites in AL, CA, MO +1
What this study is about
Researchers are testing whether Finerenone, a treatment, is effective and safe compared to placebo in people with heart failure who cannot take steroidal mineralocorticoid receptor antagonists (sMRA). The trial will last 1349 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Finerenone
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
finerenone
oral (Oral Tablet)
Primary: Number of adverse events leading to discontinuation of study drug., Number of serious adverse events
Secondary: Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) from baseline to Month 6.
Cardiology / Heart